{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T21:59:51Z","timestamp":1770242391567,"version":"3.49.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"funder":[{"name":"Universit\u00e4tsklinikum W\u00fcrzburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Hintergrund<\/jats:title>\n                    <jats:p>Durch beh\u00f6rdliche Sicherheitsempfehlungen zu Januskinaseinhibitoren (JAKi) kam es zu einem deutlichen R\u00fcckgang der Neuverordnungen in Deutschland. In der Zwischenzeit erschienen auch differenzierte Handlungsempfehlungen von Fachgesellschaften.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ziel der Arbeit<\/jats:title>\n                    <jats:p>Es sollte mittels des RHADAR-Registers untersucht werden, ob sich die Verordnungen in der Folge wieder erholten.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material und Methoden<\/jats:title>\n                    <jats:p>Retrospektive Analyse der Neuverordnungen von JAKi, TNF-Inhibitoren (TNFi) und IL-6-Rezeptor-Inhibitoren (IL-6Ri) bei Patient:innen mit rheumatoider Arthritis zwischen dem 01.04.2020 und dem 30.09.2024. Prim\u00e4rer Endpunkt war der relative Anteil der JAKi-Neuverordnungen an allen Neuverordnungen dieser 3\u00a0Substanzklassen pro Halbjahr. Zus\u00e4tzlich wurde die Therapielinie bei JAKi erfasst.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ergebnisse<\/jats:title>\n                    <jats:p>\n                      Insgesamt wurden 3492 Behandlungsneubeginne im Register im Zeitraum erfasst (TNFi:\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u20091770, 50,7\u202f%, JAKi:\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u20091269, 36,3\u202f%, IL-6Ri:\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u2009453, 13,0\u202f%). Der Anteil von JAKi stieg zun\u00e4chst von 29,5\u202f% (Quartal [Q]\u00a02\u2013Q3\/2020) auf 46,9\u202f% (Q2\u2013Q3\/2021) und fiel nach den beh\u00f6rdlichen Sicherheitsempfehlungen auf 24,4\u202f% (Q2\u2013Q3\/2023). Seit Q4\/2023 ist ein Wiederanstieg zu verzeichnen (32,8\u202f%), jedoch ohne das Vorniveau wieder zu erreichen. JAKi wurden zunehmend aus den vorderen in die fortgeschrittenen Therapielinien verdr\u00e4ngt (\u2265\u202f3.\u00a0Linie).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Schlussfolgerung<\/jats:title>\n                    <jats:p>Nach dem R\u00fcckgang der JAKi-Neuverordnungen durch die EMA-Sicherheitshinweise kam es zuletzt zu einem Wiederanstieg. JAKi werden seither bevorzugt in fortgeschrittenen Therapielinien eingesetzt, was auf einen differenzierteren Einsatz dieser Substanzklasse hindeutet.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00393-025-01728-7","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T12:33:19Z","timestamp":1758630799000},"page":"73-79","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Wiederanstieg der Januskinaseinhibitor-Neuverordnungen","Renewed increase in new Janus kinase inhibitor prescriptions"],"prefix":"10.1007","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3168-7074","authenticated-orcid":false,"given":"Patrick-Pascal","family":"Strunz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linus Maximilian","family":"Risser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Englbrecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torsten","family":"Witte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Fr\u00f6hlich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Schmalzing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Gernert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Heck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Bartz-Bazzanella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cay","family":"von der Decken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsten","family":"Karberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Gauler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanna","family":"Sp\u00e4thling-Mestekemper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Kuhn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Vorbr\u00fcggen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Welcker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Kleinert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,23]]},"reference":[{"key":"1728_CR1","doi-asserted-by":"publisher","first-page":"1445680","DOI":"10.3389\/fimmu.2024.1445680","volume":"15","author":"PP Strunz","year":"2024","unstructured":"Strunz\u00a0PP, Risser\u00a0LM, Englbrecht\u00a0M, Witte\u00a0T, Froehlich\u00a0M, Schmalzing\u00a0M et\u00a0al (2024) Use of Janus kinase inhibitors before and after European Medicines Agency safety recommendations: a\u00a0retrospective study. Front Immunol 15:1445680. https:\/\/doi.org\/10.3389\/fimmu.2024.1445680","journal-title":"Front Immunol"},{"issue":"4","key":"1728_CR2","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg\u00a0SR, Bhatt\u00a0DL, Mikuls\u00a0TR, Koch\u00a0GG, Fleischmann\u00a0R, Rivas\u00a0JL et\u00a0al (2022) Cardiovascular and cancer risk with Tofacitinib in rheumatoid arthritis. N\u00a0Engl J Med 386(4):316\u2013326. https:\/\/doi.org\/10.1056\/NEJMoa2109927","journal-title":"N Engl J Med"},{"key":"1728_CR3","unstructured":"Krause A, Kr\u00fcger K, Deutsche Gesellschaft f\u00fcr Rheumatologie Januskinase-Inhibitoren (JAKi) \u2013 wie ist mit den neuen Verordnungseinschr\u00e4nkungen umzugehen? https:\/\/dgrh.de\/dam\/jcr:2bfe3adf-b69c-47bb-9a08-acf4c8d432db\/230317_SN%20JAKi%20DGRh_final_publiziert_Korr%20AK_publiziert.pdf (Erstellt: 17. M\u00e4rz 2023). Zugegriffen: 25. Mai 2025"},{"issue":"4","key":"1728_CR4","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1002\/acr.25268","volume":"76","author":"S Song","year":"2024","unstructured":"Song\u00a0S, England\u00a0BR, Sauer\u00a0B, George\u00a0MD, Riley\u00a0TR, Wallace\u00a0B et\u00a0al (2024) Changes in characteristics of patients initiating and discontinuing advanced therapies for rheumatoid arthritis following the release of safety data. Arthritis Care Res 76(4):463\u2013469. https:\/\/doi.org\/10.1002\/acr.25268","journal-title":"Arthritis Care Res"},{"issue":"1","key":"1728_CR5","doi-asserted-by":"publisher","first-page":"e002735","DOI":"10.1136\/rmdopen-2022-002735","volume":"9","author":"GR Burmester","year":"2023","unstructured":"Burmester\u00a0GR, Cohen\u00a0SB, Winthrop\u00a0KL, Nash\u00a0P, Irvine\u00a0AD, Deodhar\u00a0A et\u00a0al (2023) Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD Open 9(1):e2735\u2013PMC9923346. https:\/\/doi.org\/10.1136\/rmdopen-2022-002735","journal-title":"RMD Open"},{"issue":"Suppl\u00a01","key":"1728_CR6","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/S0003-4967(25)02501-4","volume":"84","author":"GR Burmester","year":"2025","unstructured":"Burmester\u00a0GR, Cohen\u00a0SB, Deodhar\u00a0A, Mysler\u00a0E, Rubbert-Roth\u00a0A, Tanaka\u00a0Y et\u00a0al (2025) Long-term safety of Upadacitinib across rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis encompassing ~17,000 patient-years of clinical trial data. Rheum Dis 84(Suppl\u00a01):1185\u20131186. https:\/\/doi.org\/10.1016\/S0003-4967(25)02501-4 (Poster: POS1097)","journal-title":"Rheum Dis"},{"key":"1728_CR7","unstructured":"Giles J, Charles-Schoeman C, Buch M, Dougados M, Szekanecz Z, Mikuls T et\u00a0al (2024) Use of statins and its association with major adverse cardiovascular outcomes with tofacitinib versus TNF inhibitors in a\u00a0risk-enriched population of patients with rheumatoid arthritis. Arthritis Rheumatol 76(suppl\u00a09)"},{"issue":"1","key":"1728_CR8","doi-asserted-by":"publisher","first-page":"207","DOI":"10.3390\/jcm12010207","volume":"12","author":"C Philippoteaux","year":"2022","unstructured":"Philippoteaux\u00a0C, Deprez\u00a0V, Nottez\u00a0A, Cailliau\u00a0E, Houvenagel\u00a0E, Deprez\u00a0X et\u00a0al (2022) Characteristics of patients treated with JAK inhibitors in rheumatoid arthritis before versus after VTE risk warnings. J\u00a0Clin Med 12(1):207. https:\/\/doi.org\/10.3390\/jcm12010207","journal-title":"J Clin Med"},{"key":"1728_CR9","doi-asserted-by":"publisher","first-page":"n2384","DOI":"10.1136\/bmj.n2384","volume":"374","author":"G Iacobucci","year":"2021","unstructured":"Iacobucci\u00a0G (2021) Shortages of rheumatoid arthritis drugs hit Europe after demand surges for treating covid. BMJ 374:n2384. https:\/\/doi.org\/10.1136\/bmj.n2384","journal-title":"BMJ"},{"issue":"5","key":"1728_CR10","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s00296-025-05859-7","volume":"45","author":"LM Risser","year":"2025","unstructured":"Risser\u00a0LM, Witte\u00a0T, Englbrecht\u00a0M, Strunz\u00a0PP, Froehlich\u00a0M, Schmalzing\u00a0M et\u00a0al (2025) Janus kinase inhibitors show a\u00a0longer drug survival than biologics in a\u00a0real-world cohort of patients with rheumatoid arthritis\u2014a\u00a0retrospective analysis from the RHADAR database. Rheumatol Int 45(5):100. https:\/\/doi.org\/10.1007\/s00296-025-05859-7","journal-title":"Rheumatol Int"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-025-01728-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-025-01728-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-025-01728-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T09:14:23Z","timestamp":1770196463000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-025-01728-7"}},"subtitle":["Eine Analyse der deutschen RHADAR-Datenbank","Analysis of the German RHADAR registry"],"short-title":[],"issued":{"date-parts":[[2025,9,23]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1728"],"URL":"https:\/\/doi.org\/10.1007\/s00393-025-01728-7","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,23]]},"assertion":[{"value":"18 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"P.\u00a0Bartz-Bazzanella, C.\u00a0von der Decken, K.\u00a0Karberg, G.\u00a0Gauler, S.\u00a0Sp\u00e4thling-Mestekemper, C.\u00a0Kuhn, W.\u00a0Vorbr\u00fcggen, M.\u00a0Welcker und S.\u00a0Kleinert sind Mitarbeiter von RheumaDatenRhePort (RHADAR). Alle Autoren geben keine relevanten Interessenskonflikte an. M\u00f6gliche Interessenskonflikte: P.-P.\u00a0Strunz erh\u00e4lt Forschungsf\u00f6rderungen von AbbVie (12.000\u202f\u20ac), Chugai (25.000\u202f\u20ac) und Novartis (150.000\u202f\u20ac). MS und MG erhalten Forschungsf\u00f6rderungen von Novartis (150.000\u202f\u20ac). L.M.\u00a0Risser, M.\u00a0Englbrecht, T.\u00a0Witte, M.\u00a0Fr\u00f6hlich und J.\u00a0Heck geben an, dass keine m\u00f6glichen Interessenkonflikte bestehen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Die Studie wurde der Ethikkommission der Medizinischen Hochschule Hannover (Antrag 11291_BO_K_2024) vorgelegt, welche mitteilte, dass die retrospektive Analyse klinischer Daten gem\u00e4\u00df deutschem Recht keiner ethischen Genehmigung bedarf, solange die Publikation anonymisiert erfolgt. Alle Patient:innen hatten zuvor eine schriftliche Einwilligung zum pseudonymisierten Einschluss in die RHADAR-Datenbank gegeben.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}